JP2015110588A5 - - Google Patents

Download PDF

Info

Publication number
JP2015110588A5
JP2015110588A5 JP2014263345A JP2014263345A JP2015110588A5 JP 2015110588 A5 JP2015110588 A5 JP 2015110588A5 JP 2014263345 A JP2014263345 A JP 2014263345A JP 2014263345 A JP2014263345 A JP 2014263345A JP 2015110588 A5 JP2015110588 A5 JP 2015110588A5
Authority
JP
Japan
Prior art keywords
peptide
use according
klh
formulated
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014263345A
Other languages
English (en)
Japanese (ja)
Other versions
JP5989074B2 (ja
JP2015110588A (ja
Filing date
Publication date
Priority claimed from AT0095208A external-priority patent/AT506820B1/de
Application filed filed Critical
Publication of JP2015110588A publication Critical patent/JP2015110588A/ja
Publication of JP2015110588A5 publication Critical patent/JP2015110588A5/ja
Application granted granted Critical
Publication of JP5989074B2 publication Critical patent/JP5989074B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

JP2014263345A 2008-06-12 2014-12-25 アミロイドーシス治療のための化合物 Expired - Fee Related JP5989074B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ATA952/2008 2008-06-12
AT0095208A AT506820B1 (de) 2008-06-12 2008-06-12 Vakzine gegen alzheimer-krankheit

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2011512780A Division JP2011522840A (ja) 2008-06-12 2009-06-12 アミロイドーシス治療のための化合物

Publications (3)

Publication Number Publication Date
JP2015110588A JP2015110588A (ja) 2015-06-18
JP2015110588A5 true JP2015110588A5 (enExample) 2015-11-05
JP5989074B2 JP5989074B2 (ja) 2016-09-07

Family

ID=41401983

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011512780A Pending JP2011522840A (ja) 2008-06-12 2009-06-12 アミロイドーシス治療のための化合物
JP2014073229A Expired - Fee Related JP5984867B2 (ja) 2008-06-12 2014-03-31 アミロイドーシス治療のための化合物
JP2014263345A Expired - Fee Related JP5989074B2 (ja) 2008-06-12 2014-12-25 アミロイドーシス治療のための化合物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2011512780A Pending JP2011522840A (ja) 2008-06-12 2009-06-12 アミロイドーシス治療のための化合物
JP2014073229A Expired - Fee Related JP5984867B2 (ja) 2008-06-12 2014-03-31 アミロイドーシス治療のための化合物

Country Status (14)

Country Link
US (1) US8409581B2 (enExample)
EP (1) EP2310033B1 (enExample)
JP (3) JP2011522840A (enExample)
KR (1) KR20110036039A (enExample)
CN (1) CN102123728B (enExample)
AT (2) AT509611B1 (enExample)
AU (1) AU2009257168B2 (enExample)
BR (1) BRPI0915136A2 (enExample)
CA (1) CA2723967A1 (enExample)
ES (1) ES2392789T3 (enExample)
IL (1) IL209894A (enExample)
MX (1) MX2010013657A (enExample)
RU (1) RU2491953C2 (enExample)
WO (1) WO2009149485A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120328605A1 (en) * 2010-10-27 2012-12-27 Daniel Larocque Compositions and uses
EP2686346B1 (en) * 2011-03-16 2016-12-14 Probiodrug AG Diagnostic antibody assay
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
EP2579042B1 (en) 2011-10-04 2014-07-09 Affiris AG Method for detecting Aß-specific antibodies in a biological sample
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
US9102752B2 (en) 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
EP2787347A1 (en) 2013-04-03 2014-10-08 Affiris AG Method for detecting Aß-specific antibodies in a biological sample
EP3137094B1 (en) 2014-04-29 2022-12-07 ADvantage Therapeutics, Inc. Treatment and prevention of alzheimer's disease (ad)
WO2015165964A1 (en) * 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
CN108350052A (zh) 2015-11-09 2018-07-31 英属哥伦比亚大学 淀粉样蛋白β中间区域中的表位及其构象选择性抗体
JP7452829B2 (ja) 2015-11-09 2024-03-19 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータのエピトープおよびそれに対する抗体
EP3374379A4 (en) 2015-11-09 2019-05-15 The University Of British Columbia N-TERMINAL EPITOPES IN AMYLOID BETA AND CONFORMATION-SELECTIVE ANTIBODIES
WO2018014126A1 (en) 2016-07-18 2018-01-25 The University Of British Columbia Antibodies to amyloid beta
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
CA3070085A1 (en) 2017-07-18 2019-01-24 Promis Neurosciences Inc. Antibodies to amyloid beta
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
RU2679080C1 (ru) * 2018-04-17 2019-02-05 Александр Олегович Морозов Пептид и способ лечения болезни альцгеймера
US20250186595A1 (en) 2022-02-28 2025-06-12 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN
CN115925987A (zh) * 2022-02-28 2023-04-07 安域生物科技(杭州)有限公司 基于β-淀粉样蛋白修饰的抗原多肽及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780587A (en) * 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
AU744044B2 (en) * 1998-04-06 2002-02-14 Advanced Immunit, Inc. Short peptides for treatment of neurological degenerative diseases
NO314086B1 (no) * 1998-05-08 2003-01-27 Gemvax As Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til
CA2325600A1 (en) * 1998-05-21 1999-11-25 The University Of Tennessee Research Corporation Methods for amyloid removal using anti-amyloid antibodies
US7504490B1 (en) * 1998-10-16 2009-03-17 Oscient Pharmaceuticals Corporation Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics
US20040067535A1 (en) * 2002-10-03 2004-04-08 Life Sciences Development Corp. Alzheimer's disease linked genes
CN101103969A (zh) * 2002-12-24 2008-01-16 神经化学（国际）有限公司 治疗β淀粉样蛋白相关疾病的治疗性制品
AT413945B (de) 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
EP1440981A3 (en) * 2003-01-21 2005-11-23 Research Association for Biotechnology Full-length human cdna
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
AT413946B (de) * 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
CN101137394A (zh) * 2004-10-25 2008-03-05 默克制药公司 抗addl抗体及其应用
EP1907416A2 (en) * 2005-06-17 2008-04-09 EPFL Ecole Polytechnique Fédérale de Lausanne Switch-peptides as tool for the study of fibrillogenesis
EP2808032B1 (en) * 2005-12-12 2018-08-01 AC Immune S.A. A beta 1-42 specific monoclonal antibodies with therapeutic properties
CA2638775A1 (en) * 2006-02-22 2007-08-30 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Peptide vaccine for inducing production of anti-amyloid-.beta.-peptide antibody

Similar Documents

Publication Publication Date Title
JP2015110588A5 (enExample)
UA124347C2 (uk) Циклічна динуклеотидна сполука
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
WO2014205229A8 (en) Use of high dose pridopidine for treating huntington's disease
JP2013519675A5 (enExample)
JOP20180009A1 (ar) مركبات مثبط فيروس hiv
JP2015517488A5 (enExample)
EP4643945A8 (en) Neuroactive steroids and methods of use thereof
CO2018004776A2 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
JP2016518337A5 (enExample)
JP2019516735A5 (enExample)
RU2017114352A (ru) АНТАГОНИСТЫ ИНТЕГРИНА ανβ6
EA201691789A1 (ru) Фармацевтические композиции и соли 1,2,4-оксадиазолбензойной кислоты
RU2017116740A (ru) Комбинации для лечения рассеянного склероза
JP2016510326A5 (enExample)
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
PH12015502406A1 (en) Orally administrable pharmaceutical composition for prevention or treatment of dry eye syndrome, comprising rebamipide or prodrug thereof
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
MX394782B (es) Compuestos para el tratamiento de enfermedades asociadas con una disfunción mitocondrial.
WO2015125152A3 (en) Pharmaceutical compositions of asenapine
JP2014148552A5 (enExample)
WO2016015798A9 (en) Orodispersible film composition comprising enalapril for the treatment of hypertension in a pediatric population
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
EA201991265A1 (ru) Лекарственные формы с отсроченным высвобождением, содержащие диметилфумарат